Pulmobiotics

Executive Summary

Pulmobiotics, founded in 2019 and headquartered in Barcelona, Spain, is a pioneering biotechnology company developing engineered live biotherapeutic products (eLBPs) to address serious respiratory diseases, including cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). By modifying bacteria to deliver therapeutic payloads directly to the lungs, the company aims to provide targeted, durable treatments with potentially fewer systemic side effects than conventional therapies. Pulmobiotics' platform leverages synthetic biology to engineer safe, effective microbial strains that can colonize the respiratory tract and produce therapeutic proteins or enzymes in situ. The company's lead programs are in preclinical development, focusing on degrading mucus plugs and reducing inflammation in CF and COPD. Despite being in early stages, Pulmobiotics addresses significant unmet needs in respiratory medicine, where current treatments offer limited efficacy and adherence challenges. The company has not disclosed funding rounds or partnerships to date, but its innovative approach positions it as a potential leader in the microbiome therapeutics space. With a strong scientific foundation and a growing interest in microbiome-based treatments, Pulmobiotics is poised for advancement pending successful preclinical validation and external investment. Key risks include technical hurdles in bacterial engineering for lung delivery, regulatory complexities for live biotherapeutics, and competition from established biologics and gene therapies. The company's ability to secure funding and demonstrate proof-of-concept in animal models will be critical over the next 12-18 months.

Upcoming Catalysts (preview)

• Q1 2028Initiation of First-in-Human Phase I Trial for Lead eLBP Candidate30% success
• Q4 2026Completion of Series A Financing Round60% success
• Q2 2027Strategic Partnership with a Major Respiratory Pharma Company40% success